Session » Reproductive Issues in Rheumatic Disorders Poster

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0448

A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities

10:30AM-12:30PM: Abstract Number: 0441

A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic

10:30AM-12:30PM: Abstract Number: 0442

Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0427

Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease

10:30AM-12:30PM: Abstract Number: 0430

Clues from Early Gestational Mean Arterial Pressure in Predicting Preeclampsia Risk in Systemic Lupus Erythematosus (SLE)

10:30AM-12:30PM: Abstract Number: 0439

Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

10:30AM-12:30PM: Abstract Number: 0455

Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project

10:30AM-12:30PM: Abstract Number: 0417

Contraception in Community Rheumatology Practices

10:30AM-12:30PM: Abstract Number: 0444

Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block

10:30AM-12:30PM: Abstract Number: 0437

Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0432

Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study

10:30AM-12:30PM: Abstract Number: 0445

Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum

10:30AM-12:30PM: Abstract Number: 0449

Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects

10:30AM-12:30PM: Abstract Number: 0454

Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System

10:30AM-12:30PM: Abstract Number: 0429

Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition

10:30AM-12:30PM: Abstract Number: 0420

Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0436

Family Planning in Rheumatology: A Single Center Quality Improvement Project

10:30AM-12:30PM: Abstract Number: 0422

Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

10:30AM-12:30PM: Abstract Number: 0423

Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

10:30AM-12:30PM: Abstract Number: 0418

Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice

10:30AM-12:30PM: Abstract Number: 0450

Knowledge, Attitudes, and Intention Towards HPV Vaccination Among Reproductive-Age Women with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0451

Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0433

Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study

10:30AM-12:30PM: Abstract Number: 0438

Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies

10:30AM-12:30PM: Abstract Number: 0428

Placental Characteristics in Systemic Lupus Erythematosus Pregnancies Resulting in Small for Gestational Age Infants

10:30AM-12:30PM: Abstract Number: 0419

Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0440

Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0447

Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database

10:30AM-12:30PM: Abstract Number: 0434

Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review

10:30AM-12:30PM: Abstract Number: 0426

Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center

10:30AM-12:30PM: Abstract Number: 0431

Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors

10:30AM-12:30PM: Abstract Number: 0452

Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study

10:30AM-12:30PM: Abstract Number: 0446

Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications

10:30AM-12:30PM: Abstract Number: 0453

Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family

10:30AM-12:30PM: Abstract Number: 0443

Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients

10:30AM-12:30PM: Abstract Number: 0424

The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE

10:30AM-12:30PM: Abstract Number: 0421

The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study

10:30AM-12:30PM: Abstract Number: 0425

Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0435

Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].